Calliditas Therapeutics AB (publ)
CALT · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $11 | $6 | $7 | $5 |
| - Cash | $1 | $1 | $1 | $1 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $11 | $6 | $7 | $5 |
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 89.4% | -34.6% | 53.3% | – |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 90.5% | 95.3% | 95.1% | 94.9% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -5.1% | -68.6% | 7.1% | -54% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -8.5% | -83.3% | -4.1% | -57.1% |
| EPS Diluted | -1.76 | -9.18 | -0.68 | -6.28 |
| % Growth | 80.8% | -1,250% | 89.2% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |